Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 29, 2015 9:45 PM ET

Pharmaceuticals

Company Overview of Parion Sciences, Inc.

Company Overview

Parion Sciences, Inc., a pharmaceutical company, engages in the discovery and development of new treatments for serious diseases in multiple therapeutic areas. The company primarily focuses on developing therapeutic agents for pulmonary diseases, including cystic fibrosis, chronic obstructive pulmonary disorder, and bronchiectasis. It develops epithelial sodium channel blockers that are used for the treatment of diseases associated with lung, mouth, nose, and the gastrointestinal tract. The company also develops an oral rinse for the relief of chronic dry mouth; and compounds for patients suffering from dry eyes. It was formerly known as CYFI, Inc. and changed its name to Parion Sciences, In...

2800 Meridian Parkway

Suite 195

Durham, NC 27713

United States

Founded in 1999

Phone:

919-313-1180

Fax:

919-313-1190

Key Executives for Parion Sciences, Inc.

Co-Founder, Co-Chairman and Chief Executive Officer
Age: 69
President
Co-Founder and Co-Chairman
Chief Operating Officer
Age: 49
Senior Director of Clinical & Regulatory Operations
Compensation as of Fiscal Year 2014.

Parion Sciences, Inc. Key Developments

Parion Sciences, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

Parion Sciences, Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

Parion Sciences Announces Exclusive Option Agreement for the Development and Commercialization of P-321 in Ophthalmology in Certain Asian Territories

Parion Sciences, Inc. announced that Parion and Santen Pharmaceutical Co. Ltd. have entered into the "OPTION, LICENSE AND DEVELOPMENT AGREEMENT", an exclusive option agreement for the development and commercialization of P-321 for dry eye disease in certain Asian territories. On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease. Parion plans to initiate a Phase 1/2a clinical trial in patients suffering from dry eye disease in July, 2014 in the United States. Under the terms of agreement, Santen will make an undisclosed option payment to secure certain rights to P-321 and to support the upcoming Phase 1/2a clinical trial. Should Santen elect to exercise their option, Santen will have responsibility for all clinical, regulatory, and commercial activity for the ophthalmic use of P-321 in the agreed Asian territories. Parion retains all rights to develop and commercialize P-321 in the rest of the world, including North America and Europe.

Parion Sciences Announces Executive Changes

Parion Sciences announced senior leadership and organizational changes. The changes include the following: Paul Boucher has been promoted to President and will lead the executive management team, business development and provide overall corporate direction. Paul previously served as Vice-President of Finance & Business at Parion. Joe Schachle has been appointed as Chief Operating Officer (COO) and will be responsible for corporate strategy, commercial operations, and corporate operations. Joe joined Parion from Grifols where he served as Head of Global Marketing Operations. Anita Woodring has been appointed as Senior Director of Clinical & Regulatory Operations. Anita is joining Parion from Research Triangle Institute (RTI) where she served as Regulatory Project Leader. These changes are intended to support the growth plans for the organization based on the initiation of trials across 3 clinical programs and increased efforts in early stage research projects.

Similar Private Companies By Industry

Company Name Region
Amneal Pharmaceuticals LLC United States
Sopherion Therapeutics, LLC United States
PetLife Organic, Inc. United States
Herbal Regenesis, Inc. United States
Altaire Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Parion Sciences, Inc., please visit www.parion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.